登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，6月1日，COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-06-02

  • COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study

    Songjiang Huang, Jianwen Wang, Fen Liu, Jiacheng Liu, Guijuan Cao, Chongtu Yang, Wei Liu, Chao Tu, Muxin Zhu & Bin Xiong

    Hypertension Research (2020)Cite this article

    Article

    Published: 01 June 2020

    COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study

    Songjiang Huang, Jianwen Wang, Fen Liu, Jiacheng Liu, Guijuan Cao, Chongtu Yang, Wei Liu, Chao Tu, Muxin Zhu & Bin Xiong

    Hypertension Research (2020)Cite this article

    1 Altmetric

    Metricsdetails

    Abstract

    This study aims to explore the effect of hypertension on disease progression and prognosis in patients with coronavirus disease 2019 (COVID-19). A total of 310 patients diagnosed with COVID-19 were studied. A comparison was made between two groups of patients, those with hypertension and those without hypertension. Their demographic data, clinical manifestations, laboratory indicators, and treatment methods were collected and analyzed. A total of 310 patients, including 113 patients with hypertension and 197 patients without hypertension, were included in the analysis. Compared with patients without hypertension, patients with hypertension were older, were more likely to have diabetes and cerebrovascular disease, and were more likely to be transferred to the intensive care unit. The neutrophil count and lactate dehydrogenase, fibrinogen, and D-dimer levels in hypertensive patients were significantly higher than those in nonhypertensive patients (P < 0.05). However, multivariate analysis (adjusted for age and sex) failed to show that hypertension was an independent risk factor for COVID-19 mortality or severity. COVID-19 patients with hypertension were more likely than patients without hypertension to have severe pneumonia, excessive inflammatory reactions, organ and tissue damage, and deterioration of the disease. Patients with hypertension should be given additional attention to prevent worsening of their condition.

  • 原文来源：https://www.nature.com/articles/s41440-020-0485-2
18浏览量
原文链接
相关报告

  • 《Lancet，6月24日，Tocilizumab in patients with severe COVID-19: a retrospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-26
    • Tocilizumab in patients with severe COVID-19: a retrospective cohort study Prof Giovanni Guaraldi, MD † Marianna Meschiari, MD † Prof Alessandro Cozzi-Lepri, PhD Jovana Milic, MD Roberto Tonelli, MD Marianna Menozzi, MD Published:June 24, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30173-9 Summary Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment. Methods This retrospective, observational cohort study included adults (≥18 years) with severe COVID-19 pneumonia who were admitted to tertiary care centres in Bologna and Reggio Emilia, Italy, between Feb 21 and March 24, 2020, and a tertiary care centre in Modena, Italy, between Feb 21 and April 30, 2020. All patients were treated with the standard of care (ie, supplemental oxygen, hydroxychloroquine, azithromycin, antiretrovirals, and low molecular weight heparin), and a non-randomly selected subset of patients also received tocilizumab. Tocilizumab was given either intravenously at 8 mg/kg bodyweight (up to a maximum of 800 mg) in two infusions, 12 h apart, or subcutaneously at 162 mg administered in two simultaneous doses, one in each thigh (ie, 324 mg in total), when the intravenous formulation was unavailable.
    190浏览量
    原文链接

  • 《MedRxiv，4月20日，（第2版更新）Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: A multicenter retrospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-21
    • Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: A multicenter retrospective cohort study Ziyun Shao Sr., Yongwen Feng, Li Zhong, Qifeng Xie, Ming Lei, Zheying Liu, Conglin Wang, Jingjing Ji, Huiheng Liu, Zhengtao Gu, Zhongwei Hu, Lei Su, Min Wu, Zhifeng Liu doi: https://doi.org/10.1101/2020.04.11.20061739 Abstract Importance: Coronavirus disease 2019 (COVID-19) has become pandemic, causing more than 1.5 million infections and over ten-thousands of deaths in a short period of time worldwide. However, little is known about its pathological mechanism, and reports on clinical study on specific treatment are few. Objective: The purpose of this study is to determine the clinical efficacy of intravenous immunoglobulin (IVIG) therapy in COVID-19 patients. Design, setting and participants: This multicenter retrospective cohort study enrolled 325 adult critical COVID-19 patients, including severe type and critical type, according to the clinical classification defined by National Health Commission of China, in 8 government designated treatment centers in China from Dec 23, 2019 to Mar 31, 2020. Demographic, clinical, treatment, and laboratory data as well as prognosis were extracted from electronic medical records. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    122浏览量
    原文链接